Skip main navigation
We use cookies to give you a better experience, if that’s ok you can close this message and carry on browsing. For more info read our cookies policy.
We use cookies to give you a better experience. Carry on browsing if you're happy with this, or read our cookies policy for more information.

Skip to 0 minutes and 10 secondsDAVID MANALLACK: So far, we've seen an evolution take place in this story of drug discovery. The next part of this presentation will take you through the molecular changes that have been made. The importance of this work has been to provide safe and clinically effective medicines. If side effects are apparent, well where there's too much variation in the effect of a drug from one person to another, then improvements must be made. The story of the sulfonamides, evolving to the sulfonylurea compounds, is a classic process of continual improvement. And all of this is oriented to providing better medicines for better health outcomes.

Skip to 0 minutes and 53 secondsFrom sulfanilamide, the next development was to change the right hand side to produce IPTD. From there, we developed the first sulfonylurea with a short carbon chain attached to the right hand side. Tolbutamide was next, and it gave us reduced toxicity and was much more specific for treating diabetes.

Skip to 1 minute and 21 secondsThe chlorine atom in chlorpropamide reduced the metabolism of the drug, giving it a long half life. The next generation of compounds includes glibenclamide, with its significantly modified left hand side. Glipizide shares a similar left hand side, and the identical hydrophobic right hand side for the molecule. Finally, we arrive at gliclazide, with a return to a methyl group on the left hand side, which we first saw in tolbutamide back in the 1950s. So to some extent, we've come full circle while the right hand side retains the need for a hydrophobic group.

Skip to 2 minutes and 11 secondsUnfortunately, we don't have structural information on the protein target of gliclazide. The structure of gliclazide is shown here in this animation, illustrating the overall shape of this molecule. And we see it here rotating around, demonstrating its overall structure.

Skip to 2 minutes and 34 secondsSo let's review what we've covered in this chemistry module. A drug's side effect is what led to the development of the sulfonylurea antidiuretic drugs. Indeed, drug side effects have often been exploited to develop new medicines. And the most famous case is that of Viagra. We looked at the molecular features needed for biological activity as well as those that could be modified to improve drug safety for the sulfonylurea drugs. And indeed, both the left and the right hand sides of these molecules were modified to create clinically useful compounds.

Diabetes chemistry: part 2

Watch David explain the process of optimising the chemical structures of the anti-diabetic sulfonylureas for safety and efficacy.

Share this video:

This video is from the free online course:

The Science of Medicines

Monash University

Get a taste of this course

Find out what this course is like by previewing some of the course steps before you join:

  • Introduction: the healthcare team
    Introduction: the healthcare team

    Watch Kirstie and Lyn describe health care teams and how doctors and pharmacists work together. Kirstie also provides a brief overview of the course.

  • Diabetes: patient introduction
    Diabetes: patient introduction

    Watch Kirstie introduce Shirley Park, a mildly overweight patient with Type 2 diabetes. Unfortunately for Shirley, diet and exercise have not helped.

  •  Heart disease: patient introduction
    Heart disease: patient introduction

    Watch Kirstie introduce Steve Park, an overweight 49-year-old with reflux and high blood pressure.

  • Pain patient introduction
    Pain patient introduction

    Watch Kirstie introduces Ari, a gentleman with chronic back pain on multiple medications, including morphine tablets.

  • Smoking: patient introduction
    Smoking: patient introduction

    Watch Kirstie introduce Tracey Wilson, a 28 years of age smoker who wants to quit.

  • Depression: patient introduction
    Depression: patient introduction

    Watch Kirstie introduce Maria Tarantino, a 32 years of age mother of three, including a young baby who is suffering from a depressive disorder.

  • Depression pharmaceutics
    Depression pharmaceutics

    Watch Ian combine medicine design and pharmaceutics to demonstrate how often fluoxetine needs to be taken.

Contact FutureLearn for Support